Related Experiment Video
Updated: Jun 4, 2026
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Methodological and practical challenges for personalized cancer therapies
Ignacio I Wistuba1, Juri G Gelovani, Jörg J Jacoby
1Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Abstract:
Many experts agree that personalized cancer medicine, defined here as treatment based on the molecular characteristics of a tumor from an individual patient, has great potential in the therapy of many types of cancer. Although targeted therapy agents are increasingly available for clinical applications, many of these promising drugs have produced disappointing results when tested in clinical trials, indicating that there are many challenges that must be addressed to advance this field. We propose that a new generation of clinical trials requiring biopsies to obtain relevant tumor specimens, as well as novel statistical designs, will be essential to improve treatment outcomes. However, these novel clinical trials will only be successful if appropriate biomarkers are identified to help guide the selection of the most beneficial treatments for the participating patients. Although biomarkers based on single gene mutations are the most commonly used in clinical applications today, gene-expression or protein-expression 'signatures' and new imaging technologies have the potential to play important roles as biomarkers in the future. Therefore, it is of crucial importance that we identify and resolve existing challenges that may impede the rapid identification and translation of validated biomarkers with acceptable sensitivity and specificity from the laboratory to the clinic. These challenges include limitations of current biomarker development methodologies and regulatory and reimbursement policies and practices.
Insights
Personalized cancer medicine shows promise, but clinical trials face challenges. Novel trial designs and validated biomarkers are crucial for advancing targeted cancer therapies and improving patient outcomes.
Area of Science:
- Oncology
- Translational Medicine
- Biomarker Discovery
Background:
- Personalized cancer medicine, tailoring treatments to individual tumor molecular characteristics, holds significant therapeutic potential.
- Despite the availability of targeted therapy agents, many have yielded disappointing clinical trial results, highlighting unmet needs in the field.
Purpose of the Study:
- To propose advancements in clinical trial design and biomarker identification for personalized cancer medicine.
- To address challenges hindering the translation of validated biomarkers from research to clinical practice.
Main Methods:
- Recommending a new generation of clinical trials incorporating tumor biopsies for molecular analysis.
- Advocating for novel statistical designs to enhance trial efficiency and outcome prediction.
- Emphasizing the critical role of identifying and validating appropriate biomarkers for treatment selection.
Main Results:
- Current biomarker strategies, often based on single gene mutations, require expansion.
- Gene-expression signatures, protein-expression signatures, and advanced imaging technologies show future biomarker potential.
- Existing challenges in biomarker development, regulation, and reimbursement impede clinical translation.
Conclusions:
- Novel clinical trial designs and robust biomarker strategies are essential for realizing the potential of personalized cancer medicine.
- Overcoming methodological, regulatory, and reimbursement hurdles is critical for the successful implementation of validated biomarkers.
- Future efforts must focus on the rapid and reliable translation of biomarkers to improve cancer patient care.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...